What does Dr. Geert JEURISSEN do?

Dr. Geert JEURISSEN is a specialist medical practice in Maasmechelen. Private Limited, started on 18 April 2008.

What is the address of Dr. Geert JEURISSEN?

The registered office of Dr. Geert JEURISSEN is located at St. Andreasstraat(M) 23, 3630 Maasmechelen.

Is Dr. Geert JEURISSEN still active?

Yes. According to the CBE (2 November 2026) Dr. Geert JEURISSEN is active, legal situation “Normale toestand”, started on 18 April 2008.

Is Dr. Geert JEURISSEN registered on Peppol?

Yes, Dr. Geert JEURISSEN is registered on the Peppol network with ID 0208:0897547136.

What is the enterprise number of Dr. Geert JEURISSEN?

The enterprise number of Dr. Geert JEURISSEN is BE0897547136.

When was Dr. Geert JEURISSEN founded?

Dr. Geert JEURISSEN was founded on 18 April 2008.

Who are the directors of Dr. Geert JEURISSEN?

According to the 2025 annual accounts, the directors of Dr. Geert JEURISSEN are: Geert René Jeurissen.

Is Dr. Geert JEURISSEN a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 18 April 2008; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. Geert JEURISSEN make in 2025?

Dr. Geert JEURISSEN posted a profit after taxes of € 92,972 in financial year 2025.

What is the revenue of Dr. Geert JEURISSEN?

As a small company, Dr. Geert JEURISSEN is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 115,343.

Dr. Geert JEURISSEN (Private Limited) - Maasmechelen

Dossier Dr. Geert JEURISSEN, printed on 2 November 2026 from databakkes.be/en/0897547136/dr-geert-jeurissen. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Dr. Geert JEURISSEN from Maasmechelen, company number BE0897547136, closed financial year 2025 with a result of € 92,972 after tax. For that financial year Dr. Geert JEURISSEN recorded a gross margin of € 115,343 and equity of € 1.1 million. Compared with financial year 2024, the result moved from € 131,265 to € 92,972. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 12, 2026.

What it is worth Growing

€ 1.1 million

▲ 10% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 92,972

▼ 29% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 139,097

▲ 13% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.1 million.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 10,351

▲ 193% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 358,593 Gross margin 2022: € 358,593 First fiscal year in the series	€ 367,269 Gross margin 2023: € 367,269 ▲ 2% vs 2022 (€ 358,593) Favourable step	€ 167,322 Gross margin 2024: € 167,322 ▼ 54% vs 2023 (€ 367,269) Unfavourable step	€ 115,343 Gross margin 2025: € 115,343 ▼ 31% vs 2024 (€ 167,322) Unfavourable step	▼ 31%
Profit after taxes	€ 137,350 Profit after taxes 2022: € 137,350 First fiscal year in the series	€ 256,215 Profit after taxes 2023: € 256,215 ▲ 87% vs 2022 (€ 137,350) Favourable step	€ 131,265 Profit after taxes 2024: € 131,265 ▼ 49% vs 2023 (€ 256,215) Unfavourable step	€ 92,972 Profit after taxes 2025: € 92,972 ▼ 29% vs 2024 (€ 131,265) Unfavourable step	▼ 29%
Equity	€ 782,275 Equity 2022: € 782,275 First fiscal year in the series	€ 964,042 Equity 2023: € 964,042 ▲ 23% vs 2022 (€ 782,275) Favourable step	€ 971,561 Equity 2024: € 971,561 ▲ 1% vs 2023 (€ 964,042) Favourable step	€ 1,064,533 Equity 2025: € 1,064,533 ▲ 10% vs 2024 (€ 971,561) Favourable step	▲ 10%
Total debts	€ 122,108 Total debts 2022: € 122,108 First fiscal year in the series	€ 110,963 Total debts 2023: € 110,963 ▼ 9% vs 2022 (€ 122,108) Favourable step	€ 213,361 Total debts 2024: € 213,361 ▲ 92% vs 2023 (€ 110,963) Unfavourable step	€ 102,909 Total debts 2025: € 102,909 ▼ 52% vs 2024 (€ 213,361) Favourable step	▼ 52%
Cash	€ 452,023 Cash 2022: € 452,023 First fiscal year in the series	€ 230,476 Cash 2023: € 230,476 ▼ 49% vs 2022 (€ 452,023) Unfavourable step	€ 122,976 Cash 2024: € 122,976 ▼ 47% vs 2023 (€ 230,476) Unfavourable step	€ 139,097 Cash 2025: € 139,097 ▲ 13% vs 2024 (€ 122,976) Favourable step	▲ 13%
Retained profit	€ 769,075 Retained profit 2022: € 769,075 First fiscal year in the series	€ 950,842 Retained profit 2023: € 950,842 ▲ 24% vs 2022 (€ 769,075) Favourable step	€ 958,361 Retained profit 2024: € 958,361 ▲ 1% vs 2023 (€ 950,842) Favourable step	€ 1,051,333 Retained profit 2025: € 1,051,333 ▲ 10% vs 2024 (€ 958,361) Favourable step	▲ 10%
Dividend	€ 176,372 Dividend 2022: € 176,372 First fiscal year in the series	€ 74,448 Dividend 2023: € 74,448 ▼ 58% vs 2022 (€ 176,372) Unchanged	€ 123,746 Dividend 2024: € 123,746 ▲ 66% vs 2023 (€ 74,448) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 123,746) Unchanged	▼ 100%
Bank debt	€ 15,109 Bank debt 2022: € 15,109 First fiscal year in the series	€ 0 Bank debt 2023: € 0 ▼ 100% vs 2022 (€ 15,109) Favourable step	€ 40,000 Bank debt 2024: € 40,000 Unchanged (€ 0) Unfavourable step	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 40,000) Favourable step	▼ 100%
Balance sheet total	€ 904,382 Balance sheet total 2022: € 904,382 First fiscal year in the series	€ 1,075,005 Balance sheet total 2023: € 1,075,005 ▲ 19% vs 2022 (€ 904,382) Unchanged	€ 1,184,922 Balance sheet total 2024: € 1,184,922 ▲ 10% vs 2023 (€ 1,075,005) Unchanged	€ 1,167,443 Balance sheet total 2025: € 1,167,443 ▼ 1% vs 2024 (€ 1,184,922) Unchanged	▼ 1%

Key figures of Dr. Geert JEURISSEN, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. Geert JEURISSEN?

What happened at Dr. Geert JEURISSEN in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 12, 2026 New annual accounts for financial year 2025: profit of € 92,972 (▼ 29% vs 2024). filed late Source: NBB ↗
2008 Geert René Jeurissen became a director. NBB
Apr 18, 2008 Start of the company according to the CBE. KBO

In short

From € 137,350 profit in 2022 to € 92,972 profit in 2025.

Paid € 439,685 in corporate taxes since 2022.

Best year ever: 2023, with € 256,215 profit.

Paid out € 374,566 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Geert René Jeurissen

Dr. Geert JEURISSEN

Cardiotrials ZOL 5.2%

HLG 0.1%

Behind Dr. Geert JEURISSEN is Geert René Jeurissen. It owns 5.2% of Cardiotrials ZOL and 0.1% of HLG itself.

Directors

According to the 2025 annual accounts

Geert René Jeurissen

Director

since 2008

Establishments

Establishment units

Physical locations of this company

Registered office

St. Andreasstraat(M) 23

3630 Maasmechelen

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

DR. ANN MANDERVELT

€ 249,971 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0897.547.136
VAT number: BE 0897.547.136
Registered office: St. Andreasstraat(M) 23, 3630 Maasmechelen
Names & denominations: Dr. Geert JEURISSEN
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 18 April 2008
Peppol: Active · Active since 18 Nov 2025
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗